Abstract | BACKGROUND: MATERIALS AND METHODS: We enrolled patients with a history of breast cancer, aged 20 to 70 years, who had received with tamoxifen treatment within the past 5 years. We obtained the initial data and performed a follow-up blood test and ultrasound examination to compare the differences before and after tamoxifen treatment. The patients were divided into relatively normal and fatty liver groups. RESULTS: Of the 266 enrolled tamoxifen-treated patients, 143 (53.8%) and 123 (46.2%) were in the relatively normal and fatty liver groups, respectively. The initial body weight (57.6 ± 9.3 kg vs. 60.9 ± 10.3 kg; P = .006) and body mass index (BMI; 23.4 ± 3.8 kg/m2 vs. 25.0 ± 4.2 kg/m2; P < .001) were lower in the relatively normal group. An initial BMI of ≥ 22 kg/m2 was a potential risk factor for tamoxifen-related NAFLD (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.00-2.48; P = .048). In contrast, a weekly exercise duration of ≥ 150 minutes reduced the risk (HR, 0.47; 95% CI, 0.31-0.69; P < .001). CONCLUSION: The results from our study suggest that a BMI of ≥ 22 kg/m2 is a potential risk factor for tamoxifen-related fatty liver and exercise is a possible protective factor.
|
Authors | Hong-Tai Chang, Hsiang-Ju Pan, Chien-Hung Lee |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 18
Issue 4
Pg. e677-e685
(08 2018)
ISSN: 1938-0666 [Electronic] United States |
PMID | 29287963
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Tamoxifen
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(adverse effects, therapeutic use)
- Body Mass Index
- Breast Neoplasms
(drug therapy)
- Exercise
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Non-alcoholic Fatty Liver Disease
(chemically induced, prevention & control)
- Risk Factors
- Tamoxifen
(adverse effects, therapeutic use)
- Young Adult
|